These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 26534836)

  • 1. Time-staggered inhibition of JNK effectively sensitizes chemoresistant ovarian cancer cells to cisplatin and paclitaxel.
    Seino M; Okada M; Sakaki H; Takeda H; Watarai H; Suzuki S; Seino S; Kuramoto K; Ohta T; Nagase S; Kurachi H; Kitanaka C
    Oncol Rep; 2016 Jan; 35(1):593-601. PubMed ID: 26534836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells.
    Ribeiro JR; Schorl C; Yano N; Romano N; Kim KK; Singh RK; Moore RG
    J Ovarian Res; 2016 May; 9(1):28. PubMed ID: 27184254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Chemotherapy resistance induced by interleukin-6 in ovarian cancer cells and its signal transduction pathways].
    Wang Y; Li LZ; Ye L; Niu XL; Liu X; Zhu YQ; Sun WJ; Liang YJ
    Zhonghua Fu Chan Ke Za Zhi; 2010 Sep; 45(9):691-8. PubMed ID: 21092551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemosensitizing effects of metformin on cisplatin- and paclitaxel-resistant ovarian cancer cell lines.
    Dos Santos Guimarães I; Ladislau-Magescky T; Tessarollo NG; Dos Santos DZ; Gimba ERP; Sternberg C; Silva IV; Rangel LBA
    Pharmacol Rep; 2018 Jun; 70(3):409-417. PubMed ID: 29627688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paclitaxel-exposed ovarian cancer cells induce cancer‑specific CD4+ T cells after doxorubicin exposure through regulation of MyD88 expression.
    Kim JE; Jang MJ; Jin DH; Chung YH; Choi BS; Park GB; Kim YS; Kim S; Hur DY; Hung CF; Kim D
    Int J Oncol; 2014 May; 44(5):1716-26. PubMed ID: 24573741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tubeimoside I sensitizes cisplatin in cisplatin-resistant human ovarian cancer cells (A2780/DDP) through down-regulation of ERK and up-regulation of p38 signaling pathways.
    Liu HZ; Yu C; Yang Z; He JL; Chen WJ; Yin J; Li WM; Liu HT; Wang YX
    Mol Med Rep; 2011; 4(5):985-92. PubMed ID: 21687949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ABT‑737 increases cisplatin sensitivity through the ROS‑ASK1‑JNK MAPK signaling axis in human ovarian cancer cisplatin‑resistant A2780/DDP cells.
    Li X; Guo Y; Xing Z; Gong T; Yang L; Yang T; Chang B; Wang X; Yu B; Guo R
    Oncol Rep; 2024 Sep; 52(3):. PubMed ID: 39054955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PLGA nanoparticles co-delivering MDR1 and BCL2 siRNA for overcoming resistance of paclitaxel and cisplatin in recurrent or advanced ovarian cancer.
    Risnayanti C; Jang YS; Lee J; Ahn HJ
    Sci Rep; 2018 May; 8(1):7498. PubMed ID: 29760419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells.
    Wang Y; Niu XL; Qu Y; Wu J; Zhu YQ; Sun WJ; Li LZ
    Cancer Lett; 2010 Sep; 295(1):110-23. PubMed ID: 20236757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The alkaloid emetine sensitizes ovarian carcinoma cells to cisplatin through downregulation of bcl-xL.
    Sun Q; Yogosawa S; Iizumi Y; Sakai T; Sowa Y
    Int J Oncol; 2015 Jan; 46(1):389-94. PubMed ID: 25310746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. JNK- and Akt-mediated Puma expression in the apoptosis of cisplatin-resistant ovarian cancer cells.
    Zhao Z; Wang J; Tang J; Liu X; Zhong Q; Wang F; Hu W; Yuan Z; Nie C; Wei Y
    Biochem J; 2012 Jun; 444(2):291-301. PubMed ID: 22394200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dexamethasone enhances cell resistance to chemotherapy by increasing adhesion to extracellular matrix in human ovarian cancer cells.
    Chen YX; Wang Y; Fu CC; Diao F; Song LN; Li ZB; Yang R; Lu J
    Endocr Relat Cancer; 2010 Mar; 17(1):39-50. PubMed ID: 19776289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of the response of prostate cancer cell lines to cisplatin treatment using small interfering RNA.
    Parra E; Ferreira J
    Oncol Rep; 2013 Oct; 30(4):1936-42. PubMed ID: 23900581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IGF-1R inhibition potentiates cytotoxic effects of chemotherapeutic agents in early stages of chemoresistant ovarian cancer cells.
    Singh RK; Gaikwad SM; Jinager A; Chaudhury S; Maheshwari A; Ray P
    Cancer Lett; 2014 Nov; 354(2):254-62. PubMed ID: 25157649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Approach for chemosensitization of cisplatin-resistant ovarian cancer by cucurbitacin B.
    El-Senduny FF; Badria FA; El-Waseef AM; Chauhan SC; Halaweish F
    Tumour Biol; 2016 Jan; 37(1):685-98. PubMed ID: 26242260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and characterization of five cell models for chemoresistance studies of human ovarian carcinoma.
    Li L; Luan Y; Wang G; Tang B; Li D; Zhang W; Li X; Zhao J; Ding H; Reed E; Li QQ
    Int J Mol Med; 2004 Aug; 14(2):257-64. PubMed ID: 15254775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A small molecule STAT3 inhibitor, LLL12, enhances cisplatin‑ and paclitaxel‑mediated inhibition of cell growth and migration in human ovarian cancer cells.
    Zhang R; Chen X; Fu S; Xu L; Lin J
    Oncol Rep; 2020 Sep; 44(3):1224-1232. PubMed ID: 32705214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A potent oncolytic adenovirus selectively blocks the STAT3 signaling pathway and potentiates cisplatin antitumor activity in ovarian cancer.
    Han Z; Hong Z; Gao Q; Chen C; Hao Z; Ji T; Hu W; Yan Y; Feng J; Liao S; Wu P; Wang D; Wang S; Zhou J; Ma D
    Hum Gene Ther; 2012 Jan; 23(1):32-45. PubMed ID: 21875334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oridonin effectively reverses cisplatin drug resistance in human ovarian cancer cells via induction of cell apoptosis and inhibition of matrix metalloproteinase expression.
    Ma S; Tan W; Du B; Liu W; Li W; Che D; Zhang G
    Mol Med Rep; 2016 Apr; 13(4):3342-8. PubMed ID: 26935490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical activity of the liposomal cisplatin lipoplatin in ovarian cancer.
    Casagrande N; Celegato M; Borghese C; Mongiat M; Colombatti A; Aldinucci D
    Clin Cancer Res; 2014 Nov; 20(21):5496-506. PubMed ID: 25231401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.